Insight

Improving Reporting Standards in Lung Cancer Trials

Lung Cancer/X

Dec 8, 2024, 04:24

Improving Reporting Standards in Lung Cancer Trials

Aakash Desai, Assistant Professor and Associate Director at UAB O’Neal Comprehensive Cancer Center, shared an article by William J. Phillips on LinkedIn:

“Improving Reporting Standards in Lung Cancer Trials.

A recent study published in International Association for the Study of Lung Cancer journal JTO (Articles in Press, Dec 4, 2024) highlights key gaps in reporting efficacy and toxicity in early-phase lung cancer trials:

88% of studies used subjective terms like “manageable” or “tolerable” (ISJET language) to describe toxicity.
Only 12% distinguished between Grade 1 and 2 adverse events (AEs), despite the growing relevance of chronic treatments.
These findings call for more objective and transparent reporting practices to align with modern oncology care needs. Better standards can lead to clearer data interpretation, benefiting researchers, clinicians, and patients alike.

The use of investigator-assigned subjective or judgmental efficacy and toxicity reporting in early phase clinical trials of lung cancer treatments.

Authors: William J. Phillips, et al.

Improving Reporting Standards in Lung Cancer Trials

More posts featuring Aakash Desai.

Aakash Desai cancer IASLC International Association for the Study of Lung Cancer JTO Lung cancer OncoDaily Oncology UAB O'Neal Comprehensive Cancer Center William J. Phillips

Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment

Oncologist Near Me - Lynn Schuchter: A Pioneering Leader in Cancer Care and Melanoma Research

NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%

Stanley Tucci and Throat Cancer: How He Went Against, How He Survived, and More

Senator John Fetterman Responds to OncoDaily on Pediatric Oncology Funding